Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
CAMBRIDGE, Mass. and BEIJING, China, July 05, 2017 -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will host a conference call and live webcast to discuss its global strategic collaboration with Celgene.
Investor Conference Call Details
Date & Time: Thursday, July 6, 2017, 9:00 AM EDT, 9:00 PM China Standard Time
Dial-in Numbers: 1-845-675-0437 or 1-866-519-4004 (US), 400-620-8038 or 800-819-0121 (China), +852 30186771 (Hong Kong), or +65 67135090 (International)
Conference ID Number: 49231438
A live webcast and replay will be available on BeiGene’s investor website, http://ir.beigene.com/. The dial-in replay will be available approximately two hours after the conference and will be available for two days following the event. It can be accessed by dialing 1-646-254-3697 (US), 400-632-2162 (China), +852 30512780 (Hong Kong), or +61 2 8199 0299 (International).
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 400 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for the treatment of cancer. BeiGene is working to create combination solutions aimed at having both a meaningful and lasting impact on cancer patients.
Investor/Media Contact Lucy Li, Ph.D. +1 781-801-1800 [email protected] [email protected]
